| A steep radioiodine dose response scalable to humans in sodium-iodide symporter (NIS)-mediated radiovirotherapy for prostate cancer. | |
| | |
MedLine Citation:
|
PMID: 23037808 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
The sodium-iodide symporter (NIS) directs the uptake and concentration of iodide in thyroid cells. We have extended the use of NIS-mediated radioiodine therapy to prostate cancer. We have developed a prostate tumor specific conditionally replicating adenovirus that expresses hNIS (Ad5PB_RSV-NIS). For radiovirotherapy to be effective in humans, the radioiodine dose administered in the pre-clinical animal model should scale to the range of acceptable doses in humans. We performed (131)I dose-response experiments aiming to determine the dose required in mice to achieve efficient radiovirotherapy. Efficacy was determined by measuring tumor growth and survival times. We observed that individual tumors display disparate growth rates that preclude averaging within a treatment modality indicating heterogeneity of growth rate. We further show that a statistic and stochastic approach must be used when comparing the effect of an anti-cancer therapy on a cohort of tumors. Radiovirotherapy improves therapeutic value over virotherapy alone by slowing the rate of tumor growth in a more substantial manner leading to an increase in survival time. We also show that the radioiodine doses needed to achieve this increase scaled well within the current doses used for treatment of thyroid cancer in humans.Cancer Gene Therapy advance online publication, 5 October 2012; doi:10.1038/cgt.2012.68. |
| | |
Authors:
|
M A Trujillo; M J Oneal; S McDonough; R Qin; J C Morris |
Related Documents
:
|
23031358 - Expression of androgen receptors in triple negative breast carcinomas. 21469428 - Morphological and immunohistochemical features of malignant vascular tumors with specia... 15753978 - Manganese superoxide dismutase overexpression changes plating efficiency bidirectionall... 11205268 - Quercetin-induced apoptosis in the monoblastoid cell line u937 in vitro and the regulat... 15578688 - Microsatellite distribution and indication for locoregional therapy in small hepatocell... 3056608 - Moderately differentiated neuroendocrine carcinoma of the larynx. a clinicopathologic s... |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2012-10-05 |
Journal Detail:
|
Title: Cancer gene therapy Volume: - ISSN: 1476-5500 ISO Abbreviation: Cancer Gene Ther. Publication Date: 2012 Oct |
Date Detail:
|
Created Date: 2012-10-5 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9432230 Medline TA: Cancer Gene Ther Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Department of Internal Medicine, Division of Endocrinology, Diabetes, Metabolism, Nutrition, Mayo Clinic, Rochester, MN, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Tissue inhibitor of metalloproteinases-3 transfer suppresses malignant behaviors of colorectal cance...
Next Document: Synthetic DNA immunogen encoding hepatitis B core antigen drives immune response in liver.